Pharmacokinetic profile of paclitaxel in the plasma, lung, and diaphragm following intravenous or intrapleural administration in rats

Thoracic Cancer

Volumn 6, Issue 1, 2015, Pages 43-48

  Li, Jie ^a   Tang, Jian ^a   Li, Yingjie ^a   Yu, Jianqi ^a   Zhang, Baoshi ^a   Yu, Changhai ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Diaphragm; Intrapleural administration; Lung; Paclitaxel; Plasma

Indexed keywords

EID: 84920410433     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12139     Document Type: Article

References (20)

1. Hu L, Liang G, Yuliang W, Bingjing Z, Xiangdong Z, Rufu X. Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial). Trials 2013; 14: 45-51.
2. Sawabata N, Asamura H, Goya T etal. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol 2010; 5: 1369-1375.
3. Sakakura N, Mori S, Ishiguro F etal. Subcategorization of resectable non-small cell lung cancer involving neighboring structures. Ann Thorac Surg 2008; 86: 1076-1083.
4. Liu J, Meisner D, Kwong E, Wu XY, Johnston MR. Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable Paclitaxel colloids controls lymphatic metastasis in lung cancer. Cancer Res 2009; 69: 1174-1181.
5. Perng RP, Wu MF, Lin SY, Chen YM, Lin JY, Whang-Peng J. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anticancer Drugs 1997; 8: 565-573.
6. Alberola V, Cortesi E, Juan O. Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer. Crit Rev Oncol Hematol 2002; 44 (Suppl): S31-41.
7. Matsuzaki Y, Shibata K, Yoshioka M. Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion. Ann Thorac Surg 1995; 59: 127-131.
8. Zhou JX. Practical Medical Oncology. People's Medical Publishing House, Beijing 2003; 75.
9. Wu YL. The Theory and Practice to Multi-Disciplinary Comprehensive Treatment of Lung Cancer. People's Medical Publishing House, Beijing 2000; 277.
10. Wang X, Zheng H, Zhu Z, Wei Y, Chen L. Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. J Pharm Sci 2010; 99: 4746-4752.
11. Dang C, D'Andrea G, Lake D etal. Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. Clin Breast Cancer 2008; 8: 418-424.
12. Shimomura M, Yaoi T, Itoh K etal. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines. Int J Oncol 2012; 40: 995-1004.
13. Beyer I, Cao H, Persson J etal. Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin Cancer Res 2012; 18: 3340-3351.
14. De Bree E, Rosing H, Filis D etal. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol 2008; 15: 1183-1192.
15. Shord SS, Camp JR. Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose? Biopharm Drug Dispos 2006; 27: 191-196.
16. 18 separation and UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 860: 141-144.
17. Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H. High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high- performance liquid chromatography with UV detection. BMC Clin Pharmacol 2006; 6: 2-7.
18. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation for animal to human studies revisited. FASEB J 2008; 22: 659-661.
19. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958; 18: 853-856.
20. Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 2002; 49: 499-503.